Sandra Ortiz-Cuaran· @SandraOrtizCua1 · X·· 9 小时前评分70
正文 · 原文
Impressive results of DeLLphi-305 for ES-#SCLC.
💊Tarlatamab + durvalumab vs durvalumab maintenance
- Median OS: 21.1 vs 12.7 months
- 12-month OS: 79% vs 53%
Standing ovation at #ESMO26 and concurrent @NEJM publication.
Congratulations M. Pérol @MP_3855 !
@CLCCLeonBerard
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
来源：Sandra Ortiz-Cuaran · x.com